CNS tau efflux via exosomes is likely increased in Parkinson's disease but not in Alzheimer's disease

Alzheimer's and Dementia

Volumn 12, Issue 11, 2016, Pages 1125-1131

  Shi, Min ^a   Kovac, Andrej ^a,b,c   Korff, Ane ^a   Cook, Travis J ^a   Ginghina, Carmen ^a   Bullock, Kristin M ^a,b   Yang, Li ^a   Stewart, Tessandra ^a   Zheng, Danfeng ^a,d   Aro, Patrick ^a   Atik, Anzari ^a   Kerr, Kathleen F ^e   Zabetian, Cyrus P ^a,b   Peskind, Elaine R ^a,b   Hu, Shu Ching ^a,b   Quinn, Joseph F ^f   Galasko, Douglas R ^g   Montine, Thomas J ^a   Banks, William A ^a,b   Zhang, Jing ^a,d  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^c INSTITUTE OF NEUROIMMUNOLOGY   (Slovakia)

^d PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^e UNIVERSITY OF WASHINGTON   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; Biomarkers; Blood plasma; Central nervous system protein efflux; Central nervous system derived exosomes; Parkinson's disease; Tau

Indexed keywords

TAU PROTEIN; MAPT PROTEIN, HUMAN; MAPT PROTEIN, MOUSE; NERVE CELL ADHESION MOLECULE L1;

ADULT; AGED; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD; BRAIN; CELL PERMEABILIZATION; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CLEARANCE; CONTROLLED STUDY; EXOSOME; FEMALE; FLOW; HUMAN; HUMAN TISSUE; IMMUNOASSAY; ISOTOPE LABELING; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MEMBRANE MICROPARTICLE; MOUSE; NONHUMAN; PARKINSON DISEASE; PHENOTYPE; PLASMA; PRIORITY JOURNAL; PROTEIN TRANSPORT; VERY ELDERLY; ANIMAL; BLOOD BRAIN BARRIER; C57BL MOUSE; COMPARATIVE STUDY; GENETICS; KNOCKOUT MOUSE; METABOLISM; MIDDLE AGED; PHYSIOLOGY; TRANSPORT AT THE CELLULAR LEVEL;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANIMALS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; EXOSOMES; FEMALE; HUMANS; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; MIDDLE AGED; NEURAL CELL ADHESION MOLECULE L1; PARKINSON DISEASE; TAU PROTEINS;

EID: 84994404250     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2016.04.003     Document Type: Article

References (29)

1. [1] Spillantini, M.G., Goedert, M., Tau pathology and neurodegeneration. Lancet Neurol 12 (2013), 609–622.
2. [2] Medina, M., Avila, J., The role of extracellular Tau in the spreading of neurofibrillary pathology. Front Cell Neurosci, 8, 2014, 113.
3. [3] Simon, D., Garcia-Garcia, E., Gomez-Ramos, A., Falcon-Perez, J.M., Diaz-Hernandez, M., Hernandez, F., et al. Tau overexpression results in its secretion via membrane vesicles. Neurodegener Dis 10 (2012), 73–75.
4. [4] Fiandaca, M.S., Kapogiannis, D., Mapstone, M., Boxer, A., Eitan, E., Schwartz, J.B., et al. Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes: A case-control study. Alzheimers Dement 11 (2015), 600–607.
5. [5] Simón-Sánchez, J., Schulte, C., Bras, J.M., Sharma, M., Gibbs, J.R., Berg, D., et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 41 (2009), 1308–1312.
6. [6] Edwards, T.L., Scott, W.K., Almonte, C., Burt, A., Powell, E.H., Beecham, G.W., et al. Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Ann Hum Genet 74 (2010), 97–109.
7. [7] Wills, J., Jones, J., Haggerty, T., Duka, V., Joyce, J.N., Sidhu, A., Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia. Exp Neurol 225 (2010), 210–218.
8. [8] Banks, W.A., Kastin, A.J., Fischman, A.J., Coy, D.H., Strauss, S.L., Carrier-mediated transport of enkephalins and N-Tyr-MIF-1 across blood-brain barrier. Am J Physiol 251 (1986), E477–E482.
9. [9] Shi, M., Liu, C., Cook, T.J., Bullock, K.M., Zhao, Y., Ginghina, C., et al. Plasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson's disease. Acta Neuropathol 128 (2014), 639–650.
10. [10] Cholerton, B.A., Zabetian, C.P., Quinn, J.F., Chung, K.A., Peterson, A., Espay, A.J., et al. Pacific Northwest Udall Center of excellence clinical consortium: study design and baseline cohort characteristics. J Parkinsons Dis 3 (2013), 205–214.
11. [11] Hong, Z., Shi, M., Chung, K.A., Quinn, J.F., Peskind, E.R., Galasko, D., et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 133 (2010), 713–726.
12. [12] Shi, M., Bradner, J., Hancock, A.M., Chung, K.A., Quinn, J.F., Peskind, E.R., et al. Cerebrospinal Fluid Biomarkers for Parkinson Disease Diagnosis and Progression. Ann Neurol 69 (2011), 570–580.
13. [13] Mata, I.F., Shi, M., Agarwal, P., Chung, K.A., Edwards, K.L., Factor, S.A., et al. SNCA variant associated with Parkinson disease and plasma alpha-synuclein level. Arch Neurol 67 (2010), 1350–1356.
14. [14] Shi, M., Zabetian, C.P., Hancock, A.M., Ginghina, C., Hong, Z., Yearout, D., et al. Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. Neurosci Lett 480 (2010), 78–82.
15. [15] Davson, H., Segal, M.B., The return of the cerebrospinal fluid to the blood: the drainage mechanism. Physiology of the CSF and blood-brain barriers. 1996, CRC Press, Boca Raton (FL), 489–523.
16. [16] Dragovic, R.A., Gardiner, C., Brooks, A.S., Tannetta, D.S., Ferguson, D.J., Hole, P., et al. Sizing and phenotyping of cellular vesicles using Nanoparticle Tracking Analysis. Nanomedicine 7 (2011), 780–788.
17. [17] Shaw, L.M., Vanderstichele, H., Knapik-Czajka, M., Clark, C.M., Aisen, P.S., Petersen, R.C., et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 65 (2009), 403–413.
18. [18] Rissin, D.M., Kan, C.W., Campbell, T.G., Howes, S.C., Fournier, D.R., Song, L., et al. Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat Biotechnol 28 (2010), 595–599.
19. [19] Rissin, D.M., Fournier, D.R., Piech, T., Kan, C.W., Campbell, T.G., Song, L., et al. Simultaneous detection of single molecules and singulated ensembles of molecules enables immunoassays with broad dynamic range. Anal Chem 83 (2011), 2279–2285.
20. [20] Neselius, S., Zetterberg, H., Blennow, K., Randall, J., Wilson, D., Marcusson, J., et al. Olympic boxing is associated with elevated levels of the neuronal protein tau in plasma. Brain Inj 27 (2013), 425–433.
21. [21] Randall, J., Mortberg, E., Provuncher, G.K., Fournier, D.R., Duffy, D.C., Rubertsson, S., et al. Tau proteins in serum predict neurological outcome after hypoxic brain injury from cardiac arrest: results of a pilot study. Resuscitation 84 (2013), 351–356.
22. [22] Zetterberg, H., Wilson, D., Andreasson, U., Minthon, L., Blennow, K., Randall, J., et al. Plasma tau levels in Alzheimer's disease. Alzheimers Res Ther, 5, 2013, 9.
23. [23] Kenwrick, S., Watkins, A., De Angelis, E., Neural cell recognition molecule L1: relating biological complexity to human disease mutations. Hum Mol Genet 9 (2000), 879–886.
24. [24] Kiefel, H., Bondong, S., Hazin, J., Ridinger, J., Schirmer, U., Riedle, S., et al. L1CAM: a major driver for tumor cell invasion and motility. Cell Adh Migr 6 (2012), 374–384.
25. [25] Debiec, H., Christensen, E.I., Ronco, P.M., The cell adhesion molecule L1 is developmentally regulated in the renal epithelium and is involved in kidney branching morphogenesis. J Cell Biol 143 (1998), 2067–2079.
26. [26] Allory, Y., Matsuoka, Y., Bazille, C., Christensen, E.I., Ronco, P., Debiec, H., The L1 cell adhesion molecule is induced in renal cancer cells and correlates with metastasis in clear cell carcinomas. Clin Cancer Res 11 (2005), 1190–1197.
27. [27] Bartels, A.L., Blood-brain barrier P-glycoprotein function in neurodegenerative disease. Curr Pharm Des 17 (2011), 2771–2777.
28. [28] Desai, B.S., Monahan, A.J., Carvey, P.M., Hendey, B., Blood-brain barrier pathology in Alzheimer's and Parkinson's disease: implications for drug therapy. Cell Transplant 16 (2007), 285–299.
29. [29] Kang, J.H., Irwin, D.J., Chen-Plotkin, A.S., Siderowf, A., Caspell, C., Coffey, C.S., et al. Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol 70 (2013), 1277–1287.